Pipeline
CNM supports early-stage drug discovery projects from Emory leaders to advance novel therapeutics towards the clinic. Read more below about projects currently in our pipeline as well as opportunities to apply for a Therapeutic Advancement Award.
2025 Competitive RFP
CNM invites applications for the 2025 Therapeutic Advancement Awards, which provide support to Emory faculty* for advancing promising, early-stage translational projects through the CNM therapeutic discovery pipeline. Through the financial and programmatic support provided, CNM aims to advance both the progression of projects towards the clinic as well as the value of their intellectual property at each stage of the pipeline.
The 2025 RFP cycle is disease-agnostic, seeking promising (i.e. well-established disease biology and mechanistic insight) early-stage drug discovery projects, including assay development and miniaturization, high-throughput screening, hit identification, lead optimization (medicinal chemistry), and preliminary pharmacological analyses. If you would like to set up a time to discuss your project with CNM, click here.
To submit your project for consideration, please fill out the letter of intent (LOI) by clicking the button below.
The LOI window closes on Friday, January 31st.
*If you have any questions and/or concerns, including questions about eligibility, please reach out to us at newmedicines@emory.edu.
